Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib + atezolizumab + paclitaxel in unresectable or metastatic triple-negative breast cancer
jRCT2080225093Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Ipatasertib + atezolizumab + paclitaxel with Placebo + atezolizumab + paclitaxel (2 arms). Primary endpoints: Progression-free survival (PFS) and Overall survival (OS). Started Feb 2020; status: completed.
02
Drugs
ipatasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080225093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225093.